How new therapeutics could be developed to treat obesity

Embargoed until: Publicly released: 2022-03-25 05:00

Australia; VIC

What does this mean?

Jump to: MultimediaAttachmentsExpert Reaction

Researchers from Monash University have harnessed cutting-edge technology to fill key gaps in our understanding of how promising new therapeutics could work for the treatment of obesity. A class of drug candidates known as DACRAs, dual amylin and calcitonin receptor agonists, have recently caused a buzz of excitement due to promising results of the peptide drug, cagrilinide (Novo Nordisk) in clinical trials for obesity. However, until now, the details of how this class of drugs activate the different receptors was not known, therefore limiting their optimisation as a treatment for obesity. This new understanding uncovered by the team of researchers is critical to the progression of this therapeutic class.